Bozkus and colleagues demonstrated that mutated-CALR can be seen as a shared neoantigen, potentially eliciting antigen-specific response from both CD4+ and CD8+ T cells against MPN transformed cells. The gene discussed is CD8A; the disease is myeloproliferative neoplasm.